[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370462-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370462-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-recurrence-risk-with-bdmard-treatment-in-patients-with-rheumatoid-arthritis-and-a-history-of-cancer-a-nationwide-danish-register-based-cohort-study","Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer - a nationwide Danish register-based cohort study","","Investigating cancer recurrence risk in rheumatoid arthritis (RA) patients with a prior solid cancer in remission, the study compares biological DMARD (bDMARD) treatment against conventional synthetic DMARD (csDMARD) therapy. A nationwide Danish registry-based cohort identifies patients starting bDMARDs (any bDMARD, TNF inhibitors, or rituximab) or csDMARDs, then follows them from 2002 to 2021 using validated cancer-specific recurrence algorithms. Inverse probability weighting and weighted cause-specific Cox models estimate hazard ratios. No statistically significant increased recurrence risk is found overall or for breast cancer recurrence specifically, concluding no evidence of excess risk with bDMARDs in routine practice.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-recurrence-risk-with-bdmard-treatment-in-patients-with-rheumatoid-arthritis-and-a-history-of-cancer-a-nationwide-danish-register-based-cohort-study/370462/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-recurrence-risk-with-bdmard-treatment-in-patients-with-rheumatoid-arthritis-and-a-history-of-cancer-a-nationwide-danish-register-based-cohort-study/370462.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which cancer types in remission were included for the recurrence analysis?","Question",{"text":63,"@type":64},"The study includes six algorithm-specific solid cancers in remission: breast, colorectal, melanoma, bladder, endometrial, and lung.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were cancer recurrence outcomes identified in the cohort?",{"text":68,"@type":64},"Patients were followed from 2002 to 2021 using validated cancer-specific recurrence algorithms in a Danish registry setting.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the main finding regarding cancer recurrence risk with bDMARDs versus csDMARDs?",{"text":72,"@type":64},"No statistically significant increased hazard ratios for cancer recurrence were observed for any bDMARD, TNFi, or rituximab compared with csDMARD treatment, and breast cancer recurrence specifically also showed no increased risk.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370462,1790663283,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Rheumatoid arthritis  \nTo cite: Westermann R, Cordtz R, Duch K, et al.  \nCancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish registerbased cohort study. RMD Open 2025;11:e005247 . doi:10 . 1136/ rmdopen-2024-005247  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[rmdopen-2024-005247](rmdopen-2024-005247)) .  \nReceived 13 November 2024 Accepted 3 April 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Rasmus Westermann; [raw@rn.dk](raw@rn.dk)  \nORIGINAL RESEARCH  \nCancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study  \nRasmus Westermann  ,1,2 René Cordtz,1 Kirsten Duch,1,3 Lene Mellemkjaer,4 Merete Lund Hetland  ,5,6 Linda Aagaard Rasmussen,7 Lene Dreyer1  \nABSTRACT  \nObjective To investigate the risk of cancer recurrence in patients with rheumatoid arthritis (RA) and a prior solid cancer in remission treated with biological diseasemodifying antirheumatic drugs (bDMARDs) compared with those who received only conventional synthetic DMARDs (csDMARDs) .  \nMethods Nationwide registry-based cohort study of Danish patients with RA and one of the six algorithmspecific solid cancers in remission (breast, colorectal, melanoma, bladder, endometrial and lung) who initiated treatment with a bDMARD or a csDMARD. Three bDMARD exposure groups were defined according to the type(s) of bDMARD initiated: (1) any bDMARD,(2) tumour necrosis factor inhibitors (TNFi) and (3) rituximab. Patients were identified in Danish Rheumatology Quality Register and followed for cancer recurrence from 2002 to 2021 using validated cancer-specific recurrence algorithms. Inverse probability of treatment weighting and weighted causespecific Cox models were used to calculate HRs for cancer recurrence in each bDMARD exposure group compared with a csDMARD-treated group.  \nResults Among 720 unique patients with RA and an algorithm-specific solid cancer in remission, 170 any bDMARD, 81 TNFi, 99 rituximab and 651 csDMARD initiators were identified. No statistically significant increased HRs for cancer recurrence were found with any type of bDMARD 0.92 (95% CI 0.38 to 1.73), TNFi 1.10 (95% CI 0.21 to 3 . 16) or rituximab 0.94 (95% CI 0.32 to 2 . 11) . Also, no increased HRs were shown for breast cancer recurrence specifically.  \nConclusion No indications of increased cancer recurrence risk were found for bDMARDs as used in clinical practice in patients with RA and a solid cancer in remission when compared with csDMARD treatment.  \nINTRODUCTION  \nThe increased cancer incidence inpatients with rheumatoid arthritis (RA) has been extensively studied.1 2 Biological  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Few studies have investigated cancer recurrence risk associated with the use of biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) and a history of cancer.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ In patients with RA and a solid cancer in remission, this study found no evidence of increased cancer recurrence risk for treatment with any bDMARD, tumour necrosis factor inhibitors (TNFi) or rituximab, respectively, when compared with conventional synthetic DMARDs.\u003Cbr>⇒ Using validated algorithms to identify cancer recurrences in a nationwide setup, this study constitutes one of the first with an explicit definition of cancer recurrence risk with bDMARD use in RA.\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ This study provides guidance to clinicians on the safety of bDMARDs, with the findings indicating that both TNFi and ritux","cbCaitsQ27a90643","https://ap.wps.com/l/cbCaitsQ27a90643","pdf",1446333,12,"English","# Abstract\n# Objective\n# Methods\n# Results\n# Conclusion\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"Which cancer types in remission were included for the recurrence analysis?\",\"answer\":\"The study includes six algorithm-specific solid cancers in remission: breast, colorectal, melanoma, bladder, endometrial, and lung.\"},{\"question\":\"How were cancer recurrence outcomes identified in the cohort?\",\"answer\":\"Patients were followed from 2002 to 2021 using validated cancer-specific recurrence algorithms in a Danish registry setting.\"},{\"question\":\"What was the main finding regarding cancer recurrence risk with bDMARDs versus csDMARDs?\",\"answer\":\"No statistically significant increased hazard ratios for cancer recurrence were observed for any bDMARD, TNFi, or rituximab compared with csDMARD treatment, and breast cancer recurrence specifically also showed no increased risk.\"}]","Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer - a nationwide Danish register-based cohort study | PDF",1790188666,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8b0ce1a9ccbf2892b6386a750f3662f.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/788c71935eb3b889dcd72439116d33be.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4254a606ac1014c540fcb2e794a5b026.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e2f0f9704051296fa9e02bd97c6106b.webp",980,1306]